Disease activity in ankylosing spondylitis: Selection of a core set of variables and a first step in the development of a disease activity score

British Journal of Rheumatology

Volumn 35, Issue 9, 1996, Pages 867-873

  Creemers, M C W ^a   Van 'T Hof, M A ^b   Franssen, M J A M ^c   Van De Putte, L B A ^a   Gribnau, F W J ^a   Van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c St Maartens Hospital   (Netherlands)

Author keywords

Ankylosing spondylitis; Disease activity; Outcome; Validity

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CERVICAL SPINE; DISCRIMINANT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFLAMMATION; JOINT MOBILITY; LONGITUDINAL STUDY; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SCORING SYSTEM; SYMPTOM;

ADOLESCENT; ADULT; DISCRIMINANT ANALYSIS; DOUBLE-BLIND METHOD; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SPONDYLITIS, ANKYLOSING; TIME FACTORS;

EID: 1542469364     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Guidelines for the clinical evaluation of anti-inflammatory and anti-rheumatic drugs (adults and children). US Department of Health and Human Services, Public Health Service, Food and Drug Administration, April 1988, pp. 38-40.
2. Guidelines for the clinical investigation of drugs used in rheumatic diseases, European drug guideline series 5. World Health Organization, Regional office for Europe, Copenhagen, European League Against Rheumatism, March 1985, p. 12.
3. Laurent MR, Buchanan WW, Bellamy N. Methods of assessment used in ankylosing spondylitis clinical trials: a review. Br J Rheumatol 1991;30:326-9.
4. Rigby AS, Silman AJ. Outcome assessment in clinical trials of ankylosing spondylitis. Br J Rheumatol 1991;30:321-5.
5. Moll JMH, Wright V. Normal range of spinal mobility. Ann Rheum Dis 1971;30:381-6.
6. Espinoza LR, Gaylord SW, Bocanegra TS, Vasey FB, Germain BF. Circulating immune complexes in the seronegative spondyloarthropathies. Clin Immunol Immunopathol 1982;22:384-93.
7. Laurent MR, Panayi GS. Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis 1983;42:524-8.
8. Vinje O, Moller P, Mellbye J. Immunological variables and acute-phase reactants in patients with ankylosing spondylitis (Bechterew's syndrome) and their relatives. Clin Rheumatol 1984;3:501-14.
9. Cowling P, Ebringer R, Cawdell D, Ishii M, Ebringer A. C-reactive protein, ESR and Klebsiella in ankylosing spondylitis. Ann Rheum Dis 1980;39:45-9.
10. Scott DGI, Ring EFJ, Bacon PA. Problems in the assessment of disease activity in ankylosing spondylitis. Rheumat Rehabil 1981;20:74-80.
11. Calguneris M, Swinburne L, Shinebaum R, Cooke EM, Wright V. Secretory IgA: Immune defence pattern in ankylosing spondylitis and Klebsiella. Ann Rheum Dis 1981;40:600-4.
12. Hickling P, Turnbull L, Dixon JS. The relationship between disease activity, immunoglobulins and lymphocyte sub-populations in ankylosing spondylitis. Rheum Rehabil 1982;21:145-50.
13. Sanders KM, Hertzman A, Escobar MR, Littman BH. Correlation of immunoglobulin and C-reactive protein levels in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1987;46:273-6.
14. Collado A, Sanmarti R, Brancos MA et al. Correlation of immunoglobulin and C-reactive protein levels in ankylosing spondylitis. Ann Rheum Dis 1987;46:719-20.
15. Kendall MJ, Lawrence DS, Shuttleworth GR, Whitfield AGW. Haematology and biochemistry of ankylosing spondylitis. Br Med J 1973;23:235-7.
16. Dixon JS, Bird HA, Wright V. A comparison of serum biochemistry in ankylosing spondylitis, seronegative and seropositive rheumatoid arthritis. Ann Rheum Dis 1981;40:404-8.
17. 1 antitrypsin complexes in ankylosing spondylitis. Ann Rheum Dis 1989;48:30-4.
18. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
19. Creemers MCW, Franssen MJAM, Putte van de LBA, Gribnau FWJ, Riel van PLCM. Metrotrexate in severe ankylosing spondylitis; an open study. J Rheumatol 1995;22:1104-7.
20. Schober P. Lendenwirbelsaule und Kreuzschmerzen. Muench Med Wochenschr 1937;84:336.
21. Adrichem JAM, Korst van der JK. Assessment of the flexibility of the lumbar spine. Scand J Rheumatol 1973;2:87-91.
22. Domján L, Nemes T, Bálint GP, Tóth Z, Gömör B. A simple method for measuring lateral flexion of the dorsolumbar spine. J Rheumatol 1990;17:663-5.
23. Mander MM, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.
24. Creemers MCW, van't Hof MA, Franssen MJAM, Putte van de LBA, Gribnau FWJ, Riel van PLCM. A Dutch version of the functional index for ankylosing spondylitis. Development and validation in a long-term study. Br J Rheumatol 1994;33:824-6.
25. Dougados M, Gueguen A, Nakache J-P, Nguyen N, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988;15:302-7.
26. Dougados M, Gueguen A, Nakache J-P, Nguyen N, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1990;17:1254-5.
27. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
28. van 't Hof MA, Kowalski CJ. In: Prahl Anderson B, Kowalski CH, Heyendaal P, eds. A mixed longitudinal interdisciplinary study of growth and development. New York: Academic Press, 1979:161-72, 387-91.
29. Calin A, McShane D, Powers R. Objective measurements in evaluating drug therapy in ankylosing spondylitis. Curr Ther Res 1978;24:838-42.
30. Franssen MJAM, Gribnau FWJ, Putte van de LBA. Assessment of disease activity in ankylosing spondylitis: the common clinical criteria and an index of disease activity. Thesis. The Netherlands: Catholic University Nijmegen, 1985.
31. Peeters AJ, Wall Bake van den AWL, Albada-Kuipers GA et al. IgA containing immune complexes and hematuria in ankylosing spondylitis. A prospective longitudinal study. J Rheumatol 1988;15:1662-7.
32. Kennedy LG, Edmunds L, Calin A. The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol 1993;20:688-92.
33. Garrett SL, Kennedy LG, Whitelock HC et al. A new approach to defining disease status in AS: the Bath ankylosing spondylitis disease activity index (BASDAI). Br J Rheumatol 1993;32(suppl. 2):23.
34. Salaffi F, Carotti M, Brecciaroli D, Cervini C. Assessment of ankylosing spondylitis: a first step in the development of a composite index. Rev Esp Reumatol 1993;20(suppl. 1):489.
35. van de Heijde DMFM, van 't Hof MA, van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.